Insights into the interplay between Epstein-Barr virus (EBV) and multiple sclerosis (MS): A state-of-the-art review and implications for vaccine development.
作者信息
Mohammadzamani Mahtab, Kazemzadeh Kimia, Chand Swati, Thapa Sangharsha, Ebrahimi Narges, Yazdan Panah Mohammad, Shaygannejad Vahid, Mirmosayyeb Omid
机构信息
Isfahan Neurosciences Research Center Isfahan University of Medical Sciences Isfahan Iran.
Students' Scientific Research Center Tehran University of Medical Sciences Tehran Iran.
出版信息
Health Sci Rep. 2024 Feb 15;7(2):e1898. doi: 10.1002/hsr2.1898. eCollection 2024 Feb.
BACKGROUND AND AIMS
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS). MS results from an inflammatory process leading to the loss of neural tissue and increased disability over time. The role of Epstein Barr Virus (EBV), as one of the most common global viruses, in MS development has been the subject of several studies. However, many related questions are still unanswered. This study aimed to review the connection between MS and EBV and provide a quick outline of MS prevention using EBV vaccination.
METHODS
For this narrative review, an extensive literature search using specific terms was conducted across online databases, including PubMed/Medline, Scopus, Web of Science, and Google Scholar, to identify pertinent studies.
RESULTS
Several studies proved that almost 100% of people with MS showed a history of EBV infection, and there was an association between high titers of EBV antibodies and an increased risk of MS development. Various hypotheses are proposed for how EBV may contribute to MS directly and indirectly: (1) Molecular Mimicry, (2) Mistaken Self, (3) Bystander Damage, and (4) Autoreactive B cells infected with EBV.
CONCLUSION
Given the infectious nature of EBV and its ability to elude the immune system, EBV emerges as a strong candidate for being the underlying cause of MS. The development of an EBV vaccine holds promise for preventing MS; however, overcoming the challenge of creating a safe and efficacious vaccine presents a significant obstacle.